Back to top
more

Alkermes (ALKS)

(Real Time Quote from BATS)

$26.43 USD

26.43
125,904

-0.16 (-0.60%)

Updated Oct 10, 2024 10:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Acer Therapeutics (ACER) Gets CRL for Urea Cycle Disorders Drug

by Zacks Equity Research

Acer Therapeutics' (ACER) new drug application for ACER-001 to treat urea cycle disorders faces rejection from the FDA. Share price falls 21% following the announcement.

    Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?

    by Zacks Equity Research

    Here is how Aclaris Therapeutics (ACRS) and Alkermes (ALKS) have performed compared to their sector so far this year.

    Celldex (CLDX) Initiates Phase II Chronic Skin Disorder Study

    by Zacks Equity Research

    Celldex (CLDX) initiates dosing in a mid-stage study designed to evaluate its antibody candidate, barzolvolimab, for treating patients with chronic spontaneous urticaria.

    J&J's (JNJ) Stock Outperforms Industry YTD: Here's Why

    by Zacks Equity Research

    J&J's (JNJ) Pharma unit is performing above market levels. Sales in the Consumer unit are being hurt by external supply constraints. J&J focuses on growing the MedTech segment through new products.

    Here's Why You Should Retain National Vision (EYE) For Now

    by Zacks Equity Research

    Investors are optimistic about National Vision's (EYE) better-than-expected earnings and new store growth.

    Here's Why Investors Should Retain LabCorp (LH) Stock for Now

    by Zacks Equity Research

    Investors are optimistic about LabCorp's (LH) robust Drug Development business performance and several pandemic-related developments.

    Charles River (CRL) Prospers Internationally Amid FX Headwind

    by Zacks Equity Research

    Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.

    Pfizer (PFE) to Buy 8.1% Stake in Lyme Disease Vaccine Partner

    by Zacks Equity Research

    Pfizer (PFE) is set to acquire 8.1% stake in Valneva's stock. Valneva will use the cash from this investment to support its phase III study for VLA15.

    LabCorp (LH) Gets FDA Nod for VirSeq SARS-CoV-2 NGS Test

    by Zacks Equity Research

    LabCorp's (LH) VirSeq SARS-CoV-2 NGS Test can detect specific SARS-CoV-2 strains to help health care providers make appropriate patient treatment decisions.

    Bruker (BRKR) BSI & BEST Arms Drive Growth Amid Competition

    by Zacks Equity Research

    Bruker (BRKR) Nano Group's microelectronics and semiconductor metrology tools continue to perform well with ongoing strength in bookings and backlog.

    AbbVie's (ABBV) Skyrizi Gets FDA Nod for Crohn's Disease

    by Zacks Equity Research

    The FDA approval of AbbVie's (ABBV) Skyrizi for moderately to severely active Crohn's disease was supported by data from two phase III induction studies - ADVANCE, MOTIVATE, and one maintenance study - FORTIFY.

    Walgreens (WBA) Starts COVID Jabs for 3-Year Olds & Above

    by Zacks Equity Research

    Walgreens Boots (WBA) continues to serve communities with COVID testing and vaccinations to fight the pandemic.

    Here's Why You Should Invest in Bio-Rad (BIO) Stock Now

    by Zacks Equity Research

    Investors are optimistic about Bio-Rad's (BIO) strong growth in its key product lines across several geographies.

    Exelixis (EXEL), BioInvent Tie Up for Immuno-Oncology Therapies

    by Zacks Equity Research

    Exelixis (EXEL) looks to expand its biotherapeutics development pipeline by using BioInvent's proprietary immuno-oncology screening platform and antibody library.

    ObsEva's (OBSV) Yselty Gets EU Nod to Treat Uterine Fibroids

    by Zacks Equity Research

    ObsEva's (OBSV) Yselty receives its first marketing approval in the European Union for the treatment of uterine fibroids in adult women. Shares were up 11% in pre-market trading following the news.

    Valneva (VALN) Stock Declines 59% in 3 Months: Here's Why

    by Zacks Equity Research

    Though Valneva's (VALN) COVID-19 vaccine looks promising, the European Commission's intent to terminate the advance purchase agreement for the vaccine puts the future of the company's COVID-19 vaccine program into jeopardy.

    Henry Schein (HSIC) Global Dental Arm Rebounds Amid Cost Woes

    by Zacks Equity Research

    Henry Schein's (HSIC) widespread network and channel mix along with favorable long-term trends in the dental business look encouraging.

    Rhythm Pharma (RYTM) Down on Mixed Imcivree Regulatory Updates

    by Zacks Equity Research

    The FDA approves label expansion of Rhythm Pharma's (RYTM) Imcivree to include Bardet-Biedl Syndrome patients. However, the FDA provides CRL for label expansion of the drug in Alstrom syndrome.

    Bausch (BHC) Suspends IPO Plans for Solta Medical

    by Zacks Equity Research

    Bausch (BHC) suspends its plans for the initial public offering of its Solta Medical business in light of the challenging market conditions and other factors.

    Hologic (HOLX) New Products Aid Growth, Margin Pressure Stays

    by Zacks Equity Research

    Hologic's (HOLX) core molecular diagnostics franchise is growing driven by strong uptake in newer assays such as vaginitis panel and menu within the virology product line.

    Clovis (CLVS) Up 19.4% on Upbeat Data From Solid Tumor Study

    by Zacks Equity Research

    Clovis Oncology (CLVS) reports favorable data from a study, which supports the potential clinical utility of FAP-2286, its targeted radiotherapy candidate, as a treatment for advanced solid tumors.

    Roche (RHHBY) Alzheimer's Disease Drug Data Disappoints

    by Zacks Equity Research

    Roche's (RHHBY) study evaluating crenezumab in autosomal dominant Alzheimer's disease did not slow or prevent cognitive decline in people with a specific genetic mutation that causes its early onset.

    Bruker (BRKR) Debuts Module on Ultima Multiphoton Microscopes

    by Zacks Equity Research

    Bruker's (BRKR) NeuraLight 3D Ultra module offers revolutionary 3D holographic photostimulation to support neuroscience and optogenetics research applications.

    Boston Scientific (BSX) to Broaden Stent Portfolio With Buyout

    by Zacks Equity Research

    According to Boston Scientific (BSX), M.I.Tech's product offerings complement the company's existing stent portfolio, including the differentiated AXIOS Stent and Electrocautery Enhanced Delivery System.

    Pfizer (PFE) Starts EU Submission of Variant-Adapted Vaccine

    by Zacks Equity Research

    Pfizer (PFE) and its partner BioNTech initiate rolling submission, seeking authorization of the variant-adapted version of their COVID-19 vaccine.